Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has experienced a significant increase in the demand for donor organs, particularly with a 15% year-over-year growth in DCD hearts and a remarkable 44% year-over-year rise in DCD livers, contributing to a 7% overall growth in the total transplant market for hearts, livers, and lungs combined. Despite some month-over-month fluctuations, the company has demonstrated solid growth in the DCD segment, with promising trends in lung transplantation and potential for new product launches that could drive future revenue. If TransMedics achieves projected revenues of over $120 million in 4Q24, it positions the company favorably against consensus estimates for 1Q25 and the full year 2025, reflecting optimistic growth prospects.

Bears say

TransMedics Group Inc. reported a decline in organ transplant volumes, with donor after brain death (DBD) livers and hearts experiencing year-over-year decreases of 6% and 6%, respectively, alongside a monthly decline of 13% and 12%. In contrast, the donor after cardiac death (DCD) livers exhibited growth at 52% year-over-year. Additionally, despite a slight revenue estimate increase for 2026, group multiples decreased, and growing competition, along with potential changes in reimbursement and adoption rates, pose significant risks to the company's future growth and market share.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.